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Phenotype comparison between resting Research Grade and Clinical Grade MSC. 
Figure 1: Strong correlation between different RG and CG MSC markers. 
Correlation between each pair of culture is visualized through a colored 
circle and the correlation coefficient (color defines the direction of 
relationship and the correlation coefficient indicates degree of 
association, ± 1 indicates a perfect association)  
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(without 
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correlation  
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Intensity (FMI) 
values 
 Strong correlation in markers expression for different CG 
cultures. Idem for RG cultures  
 RG and CG are close in phenotype 
 15/61 markers distinguish CG from RG 
Phenotype change upon conditioning  
Figure 3: RG and CG MSC 
markers expression is 
modulated after conditioning. 
Values obtained after 
treatments were compared to 
values obtained for resting 
MSC.  
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Phenotype change upon conditioning 
(CyTOF analysis)  
Functional Capacities Assessment  
Figure 4. Activated PBMC’s proliferation is 
reduced in presence of MSC compared to 
PBMC placed alone in culture. Proliferation 
and CFSE FMI are inversely correlated.  
  CG MSC are more sensitive to activation than RG 
 Some markers are modulated by all treatments 
  Some markers  are exclusively modulated by 1 tx. 
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    MSC Samples 
•  Adipose derived MSC were obtained from ongoing collaborations: H. Rouard (EFS); J. 
Larghéro, V. Vanneaux (Hop. St Louis); D. Noël (INSERM UMRS 1183); C. Martinaud (CTSA). 
    PBMC/ Monocytes samples  
• PBMCs were obtained from venous blood from healthy volunteer donors (EFS, Rungis, 
France) using the Lymphoprep density gradient centrifugation protocol.  
• Purified monocytes were sorted from PBMC by immunomagnetic negative selection using 
anti-human CD14 antibody complexed to magnetic particles. 
     MSC thawing, cell culture and expansion. 
•  Cells were seeded at a density of 4,000/cm2 cells. 
•  Media culture for: 
o RG : α-MEM + 10% Fetal Bovine Serum + 1ng/ml bFGF + antibiotics 
o CG : α-MEM + 5% by platelet lysate + 2U/ml heparin + antibiotics 
• Cells were kept in a 37 °C humidified incubator containing 5% CO2. 
 MSC conditioning. 
     Assessment  of markers expression by Flow cytometry and CyTOF 
• Resting and conditioned cells (flow cytometry: all conditions; CyTOF: only IFNγ) were 
trypsinized. 
• Cells were incubated with monoclonal fluorochrome-conjugated or metal-conjugated 
primary Ab against Human antigens. 
• 61 antibodies were tested by flow cytometry and 31 by CyTOF. 
     PBMC inhibition assay (CFSE test) 
• Activated PBMC were labeled with carboxyfluorescein succinimidyl ester (CFSE), and put in 
contact with resting or conditioned CG MSC (60:1 ratio) 
• After 3 days, the percentage of proliferating PBMC out of the total live cells was assessed by 
flow cytometry. 
Figure 2: Markers that show significant differential expression between 
RG and  CG cultures 
   
 IFNγ modulates sub-populations enrichment. 
Figure 3. ACCENSE-generated clusters show 20 MSC subpopulations 
based on their different phenotypic profiles. After IFNγ treatment some 
clusters are enriched  (red) and others impoverished (black) 
RESTING 
 Conditioned MSCs suppress better PBMC activated in-
vitro proliferation.  
Conclusions 
Study purpose 
Results 
Materials & Methods 
To develop an immunomodulating approach in clinical perspective, we compared: 
o Phenotype 
o Functional capacities  
vs 
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    Myasthenia Gravis (MG)  
- MG is a rare auto-immune neuromuscular disease. 
- Pathogenicity is due to autoantibodies directed against proteins of the 
neuromuscular endplate.  
- Common treatments (corticosteroids and azathioprine) trigger severe side-
effects, mandating the set-up of novel therapies. 
 
     Mesenchymal Stromal/Stem Cells (MSC) 
- MSC are non-hematopoietic multipotent progenitor cells. 
- They can modulate the immune system via soluble mediators and cell-cell 
contacts. 
- Previous studies in our new MG animal model, show that the transfer of MSC 
conditioned by peripheral blood mononucleated cells (PBMC) improved the 
clinical status of the animals.  (Sudres et al., JCI Insight 2017). 
 This study first shows that research and clinical 
grade MSC share close phenotypes. This work also  
unveils phenotypic and functional markers of MSC 
along with their modulations according to different 
treatments. The CyTOF definition of new 
subpopulations may contribute to validate a cell 
therapy product for immunomodulation purposes.  
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